Meadow Fescue Allergy Shots: The FDA-Standardized Fescue Paradox
Meadow fescue (Festuca elatior) is one of 8 FDA-standardized grass extracts (g4, 100,000 BAU/mL) yet most patients have never heard of it — while its common sibling tall fescue is not standardized. Clinically, both species share essentially identical Pooideae Group 1/5 allergens. A Polish study found meadow fescue the most common sensitization among 5 grass pollens tested (Sybilski et al. 2009).
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Meadow Fescueis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Meadow Fescue Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to meadow fescue — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of meadow fescue allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of meadow fescue immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of meadow fescue extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for meadow fescue allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing meadow fescue extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription meadow fescue immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat meadow fescue allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Meadow Fescue?
The biology, taxonomy, and clinical fingerprint of Meadow Fescue — the foundation of how SCIT targets it.
Festuca elatior (meadow fescue) — one of 8 FDA-standardized grass extracts, yet a species most patients have never encountered by name. Synonym F. pratensis is used interchangeably in allergology literature.
- Scientific name
- Festuca elatior (synonym F. pratensis)
- Family
- PoaceaeGrass family
- Type
- Cool-season perennial pasture grass pollen
- Native to
- Europe; widely naturalized in North America as pasture and meadow grass
- Allergen proteins
- Fes e 1 (major) — Group 1 beta-expansin homolog, >90% cross-reactivity with Phl p 1Fes e 5 homolog (major) — Group 5 ribonuclease-like, Pooideae-specificProfilin homolog — pan-allergen, food cross-reactivity mediator
- Particle size
- 28–35 μm
- Avoidance difficulty
- Very difficult
How Meadow Fescue Allergy Presents
Symptoms by body system — useful for distinguishing Meadow Fescue sensitivity from overlapping allergies and infections.
Respiratory
- Nasal congestion and rhinorrhea during May–July grass pollen season
- Sneezing triggered by outdoor exposure in meadows, pastures, or roadsides
- Asthma exacerbation on high grass-pollen days
- Post-nasal drip and chronic cough during the grass season
- Rhinitis symptoms that may persist from late April through early August
Ocular
- Itching and tearing during peak May–June pollen counts
- Conjunctival redness and discharge on high-count outdoor days
- Eyelid swelling following meadow or pasture exposure
- Contact lens intolerance during grass season
Dermal
- Hives from direct contact with meadow fescue or related fescue grasses
- Atopic dermatitis flare-ups during peak grass season
- Skin pruritus at pollen-exposed areas on high-count days
- Urticaria from handling freshly cut meadow grass or hay
Systemic
- Fatigue and 'allergy fog' during the May–July season
- Sleep disruption from nasal congestion
- OAS (oral tingling) from profilin cross-reactivity with raw tomato, melon, celery, peach
- Reduced outdoor activity and quality of life during peak season
The fescue on your allergy test is almost always meadow fescue — because it is FDA-standardized and has an ImmunoCAP code. The fescue in your lawn is almost always tall fescue. Clinically, it doesn't matter: the two species share the same Pooideae allergen proteins, and a meadow fescue or Timothy SCIT vial covers both. The distinction is a regulatory artifact from 19th-century agronomy, not a clinical problem.
When & Where Meadow Fescue Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: May–June across most US meadow and pasture habitats· Approximately 10–12 weeks of clinically significant exposure
US Exposure Map
21 high-intensity statesExposure intensity by state (text version)
- ME:
- High
- VT:
- High
- NH:
- High
- WA:
- Moderate
- MT:
- Moderate
- ND:
- Moderate
- MN:
- High
- WI:
- High
- MI:
- High
- NY:
- High
- MA:
- High
- OR:
- Moderate
- ID:
- Moderate
- WY:
- Moderate
- SD:
- Moderate
- IA:
- High
- IL:
- High
- IN:
- High
- OH:
- High
- PA:
- High
- NJ:
- High
- CT:
- High
- RI:
- High
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Moderate
- NE:
- Moderate
- MO:
- Moderate
- KY:
- High
- WV:
- High
- VA:
- High
- MD:
- High
- DE:
- High
- AZ:
- Low
- NM:
- Low
- KS:
- Moderate
- AR:
- Low
- TN:
- Moderate
- NC:
- Moderate
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Meadow Fescue Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Meadow fescue shares essentially complete cross-reactivity with its sister species tall fescue, and >90% cross-reactivity with Timothy via Fes e 1/5 homologs — confirming that a single Pooideae SCIT vial covers all fescue-allergic patients.
Sister species — nearly interchangeable for IgE-binding; tall fescue is the common environmental species, meadow fescue is the standardized extract
Festulolium natural hybridization possible; very high Pooideae cross-reactivity
Pooideae class effect; Oralair 5-grass covers bluegrass, not meadow fescue directly
Profilin cross-reactivity; heat-labile OAS symptoms from raw foods only
Grass Pollen–Food Profilin Syndrome
Meadow fescue pollen profilin cross-reacts with profilins in raw tomato, melon, peach, celery, and similar produce, causing oral tingling that resolves within minutes. Symptoms are heat-labile — cooking or processing the food eliminates the reaction. Systemic reactions from profilin cross-reactivity are rare (<1–2% of affected patients).
Is SCIT Right for Your Meadow Fescue Allergy?
Answer 5 questions to assess your candidacy for meadow fescue allergy shots and Pooideae-protocol SCIT.
How severe are your grass pollen symptoms during the May–July season?
The Meadow Fescue SCIT Protocol
Meadow fescue SCIT uses FDA-standardized Festuca elatior extract (g4, 100,000 BAU/mL) directly, or a Timothy or 5-grass mix vial via Pooideae cross-reactivity. The standardization of meadow fescue gives allergists the option of a precisely characterized Festuca-specific protocol.
Your allergist escalates from highly diluted meadow fescue (or Timothy equivalent) extract to the maintenance concentration. Pre-seasonal initiation 4–6 months before the May–June peak is recommended. A 30-minute post-injection observation period is required at every visit.
Ongoing maintenance injections sustain immune tolerance. The Practice Parameter confirms clinical equivalence between the meadow fescue g4 vial and Timothy g6 vial for Pooideae-sensitized patients — your allergist will select based on the full allergen panel and extract availability (Cox et al. 2011, JACI 127:S1–S55).
The Calderon 2007 Cochrane meta-analysis showed sustained benefit from Pooideae SCIT after course completion. Many patients maintain durable remission for years post-discontinuation.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Meadow Fescue SCIT
Meadow fescue SCIT efficacy is supported by the Pooideae class evidence — no meadow fescue-specific SCIT RCT has been published, but the molecular cross-reactivity with Timothy is well-confirmed and the Practice Parameter endorses clinical equivalence.
- Symptom-medication score reduction (Pooideae SCIT class)32%Frew et al. 2006, JACI 117:319, N=410 — class-equivalent for meadow fescue via Pooideae cross-reactivity
- Standardized mean difference (symptoms, 51 trials)73%Calderon et al. 2007, Cochrane Database — SMD -0.73; Pooideae class applies to Festuca elatior
- Pooideae class equivalence confirmed by Practice Parameter90%Cox et al. 2011, JACI 127:S1–S55 — meadow fescue SCIT extract is class-equivalent to Timothy for clinical use
No meadow-fescue-specific SCIT RCT has been published. Evidence extrapolates from the Pooideae class effect (Calderon 2007, Frew 2006, Cox 2011). The FDA standardization of meadow fescue extract gives it regulatory recognition, and the Sybilski 2009 Polish cohort finding — meadow fescue as the most common sensitization — underscores its clinical relevance.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Meadow Fescue SCIT Side Effects
Meadow fescue SCIT — via either a direct Festuca elatior vial or a Timothy/5-grass mix vial — shares the well-characterized safety profile of FDA-standardized Pooideae extracts.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection site swelling Expected; resolves within 2–4 hours | Rate 30–50% | Mild |
Injection site itching/redness Cold compress provides relief | Rate 25–50% | Mild |
Large local reaction (>5 cm) Prompts dose adjustment at next visit | Rate 5–10% | Moderate |
Delayed local swelling 4–8 hours post-injection; common during early build-up | Rate 5–15% | Mild |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Generalized urticaria Treated with epinephrine and antihistamine; prompts dose reduction | Rate 0.1–0.5% per injection | Moderate |
Rhinitis or conjunctivitis flare Self-resolving; antihistamine as needed | Rate 0.5–2% | Mild |
Asthma exacerbation Assess peak flow before injection; withhold if FEV1 <70% predicted | Rate 0.1–0.3% | Moderate |
Anaphylaxis 30-minute observation is mandatory; a prescribed epinephrine auto-injector must be confirmed on hand at the injection location | Rate <0.001% per injection | Severe |
A 30-minute post-injection observation period is required for all SCIT injections. Emergency epinephrine must be immediately available. Properly administered Pooideae SCIT has an excellent long-term safety record per AAAAI/ACAAI surveillance data.
SCIT vs Alternatives for Meadow Fescue
Meadow fescue-allergic patients have four evidence-based options. SCIT with an FDA-standardized meadow fescue or Timothy vial provides the most durable disease modification; SLIT tablets cover via Pooideae cross-reactivity.
| Criterion | SCITBest | SLIT (Grastek/Oralair via cross-reactivity) | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | High — Pooideae class effect (Calderon 2007) | Moderate–High (10–34% TCS reduction) | Low (meadow and pasture exposure unavoidable) | Moderate (symptomatic only) |
| 5-yr cost estimate | $3,500–$15,000 | $3,000–$8,000 | Minimal | $500–$2,000/yr |
| Duration of benefit | 7–12 years | 2–3 years post-treatment | Only while avoiding | Only while taking |
| Convenience | At-home weekly shot with Curex covering meadow fescue; first dose Virtual Shot Room–supervised | Daily at-home tablet | Very difficult outdoors | Daily |
| Safety | Excellent with observation | Very safe; first dose in clinic | Safe | Good long-term |
| Lasting effect after stopping | Yes — durable remission | Partial | No | No |
SCITBest
SLIT (Grastek/Oralair via cross-reactivity)
Avoidance
Medications
SCIT delivers the most durable benefit for meadow fescue sensitization — and with Curex you no longer trade that durability for weekly clinic trips. Curex ships the at-home allergy shot with pricing confirmed in a current program quote: a personalized immunotherapy serum sterile-compounded to USP <797> covering meadow fescue and its sister tall fescue via Pooideae cross-reactivity, with your prescribed epinephrine auto-injector confirmed on hand, the first injection from each new vial or concentration supervised live in the Virtual Shot Room, and board-certified allergist oversight — one weekly shot you give yourself at home.
What Meadow Fescue SCIT Actually Costs
Meadow fescue (Festuca elatior, g4) is FDA-standardized, supporting medical necessity for insurance coverage under allergy benefits when prescribed by a board-certified allergist. Coverage is generally equivalent to Timothy SCIT under most commercial plans. Curex at-home IgE testing identifies specific meadow fescue sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your meadow fescue allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Meadow Fescue SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
This is the meadow fescue regulatory paradox. When the FDA standardized grass allergen extracts decades ago, meadow fescue (Festuca elatior, also called F. pratensis) was the dominant pasture fescue in American agriculture and entered the standardized panel. Tall fescue (Festuca arundinacea) rose to dominance later, following the post-WWII adoption of the Kentucky-31 cultivar for transition-zone lawns. Today, most ImmunoCAP and skin-test panels use the standardized g4 meadow fescue extract. Clinically, the distinction is irrelevant: the two species share essentially identical Group 1 and Group 5 Pooideae allergen proteins, so your meadow fescue test result accurately reflects your tall fescue exposure.
Grastek (Timothy 2800 BAU) covers meadow fescue via Pooideae cross-reactivity — Phl p 1/5 cross-reacts with Fes e 1/5 homologs at >90% sequence identity. Oralair (5-grass mix) does not include meadow fescue as a named component — its five grasses are sweet vernal, orchard, perennial rye, Timothy, and Kentucky bluegrass. However, Oralair still provides cross-coverage for meadow fescue via the shared Pooideae allergen architecture. This is a common source of patient confusion: the label doesn't list meadow fescue, but the allergen proteins in Oralair's five components bind the same IgE that reacts to meadow fescue extract.
Meadow fescue sensitization is tested as ImmunoCAP g4 (serum-specific IgE) or by skin prick test with a meadow fescue extract. A positive result indicates IgE sensitization to the Fes e 1/5 allergen proteins, which due to Pooideae cross-reactivity, also confirms sensitization to tall fescue, Timothy, Kentucky bluegrass, perennial rye, orchard grass, sweet vernal, and redtop. Component-resolved diagnostics with Phl p 1 and Phl p 5 from Timothy can confirm the Pooideae pattern — a patient positive for Phl p 5 has the Pooideae sensitization pattern and can be treated with any standardized Pooideae SCIT vial.
Despite its obscurity, meadow fescue is clinically significant. A Polish study (Sybilski et al. 2009) found meadow fescue was the most common sensitization among 5 grass pollens tested in their regional cohort — suggesting that in some populations, meadow fescue sensitization may be as or more prevalent than Timothy sensitization. In North America, the ImmunoCAP g4 test is widely available and commonly included in comprehensive grass panels. Because Pooideae grasses share >90% allergen sequence identity, the prevalence of meadow fescue sensitization is inseparable from the prevalence of grass allergy in temperate North America — affecting millions of patients.
Both options are scientifically valid. FDA-standardized Festuca elatior (g4, 100,000 BAU/mL) extract is available and can be prescribed as a species-specific SCIT vial. Alternatively, the AAAAI/ACAAI Practice Parameter (Cox et al. 2011) confirms that a Timothy (g6) or 5-grass mix vial covers meadow fescue equivalently via Pooideae class cross-reactivity. Most US allergists prescribe Timothy or a multi-grass mix rather than a separate meadow fescue vial, because the clinical outcome is the same and standardized multi-grass mixes are more commonly stocked. If your allergist has a preference for the meadow fescue vial, it is a legitimate choice.
Evidence on this is mixed. Some studies show pollen immunotherapy reduces OAS symptoms (effective in approximately 74% of patients in one analysis), while others found no statistically significant reduction in food allergy despite significant hay fever improvement. The current AAAAI/ACAAI consensus is that pollen SCIT should be prescribed primarily for respiratory allergy, with OAS improvement as a potential secondary benefit that cannot be reliably predicted. The underlying mechanism — pollen profilins (Fes e 12 homolog) cross-reacting with food profilins — means that immunotherapy targeting pollen profilins may reduce OAS sensitivity, but this is not guaranteed and should not be the sole reason to pursue SCIT.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.